RT info:eu-repo/semantics/article
T1 Trends in targeted therapy usage in inflammatory bowel disease: TRENDY study of ENEIDA
A1 Gómez Labrador, Celia
A1 Ricart, Elena
A1 Iborra, Marisa
A1 Iglesias, Eva
A1 Martín Arranz, María Dolores
A1 De Castro, Luisa
A1 De Francisco, Ruth
A1 García Alonso, Francisco Javier
A1 Sanahuja, Ana
A1 Gargallo Puyuelo, Carla J.
A1 Mesonero, Francisco
A1 Casanova, María José
A1 Mañosa, Míriam
A1 Rivero, Montserrat
A1 Calvo, Marta
A1 Sierra Ausin, Mónica
A1 González Muñoza, Carlos
A1 Calvet, Xavier
A1 García López, Santiago
A1 Guardiola, Jordi
A1 Arias García, Lara
A1 Márquez Mosquera, Lucía
A1 Gutiérrez, Ana
A1 Zabana, Yamile
A1 Navarro Llavat, Mercè
A1 Lorente Poyatos, Rufo
A1 Piqueras, Marta
A1 Torrealba, Leyanira
A1 Bermejo, Fernando
A1 Ponferrada Díaz, Ángel
A1 Pérez Calle, José L.
A1 Barreiro de Acosta, Manuel
A1 Tejido, Coral
A1 Cabriada, José Luis
A1 Marín Jiménez, Ignacio
A1 Roncero, Óscar
A1 Ber, Yolanda
A1 Fernández Salazar, Luis Ignacio
A1 Camps Aler, Blau
A1 Lucendo, Alfredo J.
A1 Llaó, Jordina
A1 Bujanda, Luis
A1 Muñoz Villafranca
A1 Domènech, Eugeni
A1 Chaparro, María
A1 Gisbert, Javier P.
K1 Biologicals
K1 Productos biológicos
K1 Drugs
K1 Medicamentos
K1 Drug development
K1 Biopharmaceutics
K1 Pharmaceutical biotechnology
K1 Biotecnologia farmacèutica
K1 Inflammatory bowel diseases
K1 Enfermedad inflamatoria intestinal
K1 Crohn's disease
K1 Crohn, Enfermedad de
K1 Intestines - Diseases
K1 Intestinos - Enfermedades
K1 Ulcerative colitis
K1 Colitis ulcerosa
K1 Pharmacology
K1 Gastroenterology
K1 3209 Farmacología
K1 32 Ciencias Médicas
K1 3205.03 Gastroenterología
AB Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients from the ENEIDA registry who received their first targeted IBD treatment (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis with Machine Learning models was performed. The study included 10,009 patients [71% with Crohn’s disease (CD) and 29% with ulcerative colitis (UC)]. In CD, anti-TNF (predominantly adalimumab) were the main agents in the 1st line of treatment (LoT), although their use declined over time. In UC, anti-TNF (mainly infliximab) use was predominant in 1st LoT, remaining stable over time. Ustekinumab and vedolizumab were the most prescribed drugs in 2nd and 3rd LoT in CD and UC, respectively. Overall, the use of biosimilars increased over time. Machine Learning failed to identify a model capable of predicting treatment patterns. In conclusion, drug positioning is different in CD and UC. Anti-TNF were the most used drugs in IBD 1st LoT, being adalimumab predominant in CD and infliximab in UC. Ustekinumab and vedolizumab have gained importance in CD and UC, respectively. The approval of biosimilars had a significant impact on treatment.
PB MDPI
SN 1999-4923
YR 2024
FD 2024
LK https://uvadoc.uva.es/handle/10324/68141
UL https://uvadoc.uva.es/handle/10324/68141
LA eng
NO Pharmaceutics, 2024, Vol. 16, Nº. 5, 629
NO Producción Científica
DS UVaDOC
RD 09-ene-2025